Welcome to our dedicated page for Anavex Life Scie SEC filings (Ticker: AVXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anavex Life Sciences Corp. filings document material events for a Nevada clinical-stage biopharmaceutical issuer with common stock listed on Nasdaq under AVXL. Recent Form 8-K disclosures cover financial results releases, securities registration details for its common stock, and corporate governance matters involving board appointments, executive employment arrangements, and leadership changes.
The filings also record regulatory disclosures tied to blarcamesine, including European Medicines Agency review matters for early Alzheimer’s disease and related press-release exhibits. These documents provide formal records of the company’s public-company reporting, clinical-development communications, governance actions, compensation arrangements, and capital-market security status.
Anavex Life Sciences Corp. reported fiscal 2026 first quarter results and provided a business update focused on its lead oral blarcamesine program in early Alzheimer’s disease and other central nervous system disorders.
For the quarter ended December 31, 2025, Anavex recorded a net loss of $5.7 million, improved from a net loss of $12.1 million a year earlier. Operating expenses fell to $6.8 million from $13.6 million, reflecting lower general and administrative as well as research and development spending. Net loss per share narrowed to $0.06 from $0.14, on a higher weighted average share count of 89,029,458 basic and diluted shares, up from 84,805,974.
The company ended December 31, 2025 with $131.7 million in cash and cash equivalents, up from $102.6 million as of September 30, 2025, and total stockholders’ equity of $126.6 million, compared with $94.9 million at September 30, 2025. Management reiterated its focus on advancing blarcamesine and other pipeline candidates and hosted a webcast to discuss the quarter.
Anavex Life Sciences reported that President and CEO Christopher Missling had 125,000 stock options vest on January 6, 2026. These options have an exercise price of $8.58 per share and are shown as acquired at a price of $0, reflecting the vesting of an existing award rather than a market purchase. The options are part of a larger grant made on March 31, 2025 covering 500,000 shares, structured to vest in four equal performance-based tranches.
One milestone for this grant was achieving a Second Regulatory dialogue for blarcamesine. The filing states that the performance criteria for this milestone were met, causing this 125,000-share tranche to vest. Following the transaction, Missling directly holds 125,000 derivative securities (stock options), each representing one share of common stock, with an expiration date of March 31, 2035.
Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026. The option covers 12,500 shares of common stock at an exercise price of $8.58 per share and is exercisable until March 31, 2035.
The 12,500-share tranche comes from an earlier option grant dated March 31, 2025 for 50,000 shares that vests in four equal performance-based tranches. One milestone was achieving a second regulatory dialogue for blarcamesine, and meeting this performance criterion triggered vesting of this 12,500-share portion, which Boenisch now holds directly.
Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company focused on precision-medicine treatments for central nervous system diseases, led by its oral sigma-1 receptor agonist ANAVEX®2-73 (blarcamesine). A 508-patient Phase 2b/3 trial in early Alzheimer’s disease met its pre-specified co-primary cognitive and functional endpoints and showed supporting biomarker effects, and a long-term extension suggested sustained benefit over up to 192 weeks with a consistent safety profile.
The company submitted a Marketing Authorisation Application to the EMA for Alzheimer’s disease; in November 2025 it reported a CHMP negative trend vote and plans to request re-examination after the formal opinion. Adult Rett syndrome trials met primary and secondary endpoints, while a pediatric trial showed favorable trends on the caregiver-rated RSBQ but did not meet the CGI-I co-primary endpoint. ANAVEX®3-71 completed a safe Phase 1 study and a Phase 2 schizophrenia study met its primary safety endpoint with encouraging EEG and neuroinflammatory biomarker signals. Anavex reports a broad preclinical pipeline and a sizeable patent estate extending into the 2030s.
Anavex Life Sciences Corp. (AVXL) reported that it has released its financial results for the fiscal year ended September 30, 2025. The company filed a Form 8-K to announce that these results are presented in a separate press release dated November 25, 2025, which is attached as Exhibit 99.1. The 8-K specifies that the results and the exhibit are being furnished under Item 2.02, meaning they are not treated as filed for certain liability purposes unless expressly incorporated into future reports.
Anavex Life Sciences reported a regulatory setback: the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote following the oral explanation for the Marketing Authorization Application (MAA) of blarcamesine.
The company plans to request a re-examination once the CHMP opinion is formally adopted and to provide additional biomarker data in line with feedback from CHMP, EMA, and the Alzheimer’s disease community. A press release with further details was provided as Exhibit 99.1.
Sandra Boenisch, the PFO & Treasurer of Anavex Life Sciences Corp. (AVXL), reported a change in beneficial ownership on 10/02/2025. A derivative transaction shows acquisition of 12,500 shares underlying a stock option at an exercise price of $5.36. After the transaction, the filing reports 25,000 shares beneficially owned directly by Ms. Boenisch. The filing explains the option was originally granted on 02/20/2024 for 50,000 shares and vests in four equal tranches tied to performance milestones; one milestone (readout of the AV3-71-SZ-001 schizophrenia study) was met, causing vesting of the 12,500 tranche.
Anavex Life Sciences (AVXL) disclosed that President and CEO Christopher Missling had 125,000 stock options vest on 10/02/2025. The options carry an exercise price of $5.36 and expire on 02/20/2034.
These options are part of a 500,000-share grant made on 02/20/2024 that vests in four equal tranches tied to performance milestones, including the readout of the AV3-71-SZ-001 schizophrenia study, which was met, triggering this vesting tranche.
Following the reported transaction, 250,000 derivative securities were beneficially owned.
Sandra Boenisch, Chief Financial Officer and Treasurer of Anavex Life Sciences Corp. (AVXL), reported the vesting and exercise of a portion of a previously granted option. A stock option granted on March 31, 2025 for 50,000 shares included four performance-based vesting tranches. One milestone was achieved, vesting 12,500 shares effective 08/20/2025. The reporting entry shows an option exercise right with an $8.58 conversion price and 12,500 underlying common shares designated as direct ownership following the transaction. The Form 4 was signed 08/22/2025 by Ms. Boenisch and discloses the triggering performance milestone as publication of specified preclinical data.
Christopher U. Missling, President, CEO and Director of Anavex Life Sciences Corp. (AVXL), reported the vesting and acquisition of 125,000 option shares. The Form 4 shows that on 08/20/2025 Mr. Missling acquired 125,000 stock options by exercise of a previously granted option with an $8.58 exercise price. The exercised option became vested following satisfaction of a performance milestone tied to publication of preclinical blarcamesine prevention AD data.
The underlying option was part of a larger grant made on 03/31/2025 for 500,000 options that vest in four equal tranches based on performance milestones; this transaction reflects one tranche vesting. The Form 4 is signed by Mr. Missling on 08/22/2025.